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Abstract The objective of this study was to evaluate the cor-
relation between 25-OH vitamin D and ovarian cancer as a
diagnostic marker or recurrence disease marker. We studied
the following: (1) 61 women without gynecologic diseases,
(2) 45 women affected by benign ovarian disease, (3) 46
women with recent diagnosis of ovarian cancer, (4) 26
follow-up women with recurrent ovarian cancer, and (5) 32
follow-up women with stable ovarian cancer. The 25-OH vi-
tamin D was quantified with LUMIPULSE® G 25-OH vita-
min D on LUMIPULSE® G 1200 (Fujirebio, Japan). As a
threshold value, identified by ROC curve analysis, 20.2 ng/
mL (sensitivity 73.3 %, specificity 84 %) was chosen corre-
sponding to the limit between sufficient and insufficient 25-
OH vitamin D according to the WHO. Low 25-OH vitamin D
levels were observed in 26 % of women without gynecologic
diseases, in 80 % of women with recent diagnosis of ovarian
cancer and in 24 % women affected by benign ovarian dis-
eases (p<0.001). The follow-up study showed an insufficient
level of 25-OH vitamin D in 73 % women with recurrent
ovarian cancer and in 47 % women with stable ovarian cancer
(p<0.0003). This study showed that patients with ovarian
cancer are often insufficient in 25-OH vitamin D compared
to women with benign ovarian diseases. The women with
recurrent ovarian cancer presented more often low levels com-
pared to women with stable ovarian cancer. This study sug-
gests that 25-OH vitamin D, due to its antiproliferative prop-
erties, can be a good marker for ovarian cancer also.
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Introduction
Ovarian cancer is a devastating disease with a high reversion
rate. Due to a typically asymptomatic early stage and lack of
early diagnostic tools, the disease is usually diagnosed in a late
stage. Currently, a combination of physical examination and
serum biomarker measurement are the pillars of the diagnosis
[1].
A lot of different factors such as obesity, smoke, and diet
with a high content of starch and/or fat, can be associated to
the increase of ovarian carcinoma risk [2]. Meanwhile, a slight
decrease in risk seems to be associated with a diet rich of
fibers; carotene; vitamins C, E, and D; and unsaturated fatty
acids [3, 4].
Vitamin D is a group of five different vitamins: vitamins D1,
D2,D3,D4, andD5. VitaminD is a steroid-like hormonewhich
can be obtained from two sources: (1) exposure to ultraviolet B
radiation from sunlight, that converts 7-dehydrocholesterol to
vitamin D3 in the skin and (2) assimilation of vitamin D (D2 or
D3) in diet and supplements [5–7]. The two most important
forms with similar biological activity are vitamin D2
(ergocalciferol) and vitamin D3 (cholecalciferol).
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The 25-OH vitamin D (the sum of vitamins D2 and D3) has
an important metabolic function in a lot of tissues and systems
but, recently, its involvement in onset and progression of
many diseases including cancer is becoming increasingly ev-
ident [8–10]. In addition to mineral homeostasis, vitamin D
regulates gene expression in a lot of cellular processes, such as
apoptosis, proliferation, differentiation, and a series of
immuno-modulator processes that are directly or indirectly
associated with cancer. In the last decade, the interest of many
researches is focused on the relationship between vitamin D3
and carcinogenesis [11].
Recent studies showed that vitamin D3 levels influence
cancer development, in particular, that VDR Fok1 polymor-
phism correlated with increased risks for ovarian cancer [12].
It is already known that some cancers are more frequent in
regions where the sun exposure is lower, with a (more than
50 %) increased risk of breast, colon, prostate cancer (and
partially, pancreas and ovarian cancer plus some lymphomas)
in subjects with low vitamin D levels [10]. More recent data
indicate that vitamin D supplementation can reduce the cancer
incidence [8]. The results of these studies are not always con-
cordant and some in vitro studies could not be confirmed
in vivo. The co-occurrence of tumors or tumor markers and
low vitamin D is now the subject of many scientific research.
In this study, we evaluated the correlation between vitamin D3
levels and ovarian cancer using baseline (time of first diagno-
sis) serum samples of patients with high levels of CA125 and
HE4 (in comparison to their respective cutoff values).
Patients and methods
Patients
All subjects included in the follow-up study were patients
referred to the Oncologic Unit A, of the Policlinico Umberto
I, Rome, Italy, from January 2012 to December 2014.
Group 1 consists of 61 normal blood donors (median age
57 years, range 21–65) with clinical and ultrasound (US)
outcome negative for ovarian masses.
Group 2 consists of 45 patients with benign ovarian tu-
mors (median age 62 years, range 20–74) with clinical
and instrumental diagnosis of benign adnexal disease.
Mean diameter of the cysts was 57±30.6 mm (range
20–110).
Group 3 consists of 46 women with newly diagnosed
ovarian cancer (median age 68 years, range 28–91). Clin-
ical and histological diagnosis was defined according to
the International Federation of Gynecology and Obstet-
rics (new revised FIGO, 2014) staging [13]. Epithelial
ovarian cancer (EOC) histology and grading of the
EOC was in accordance with the current classification
and guidelines [14, 15]. Clinical and histopathological
characteristics of the 46 patients are summarized in
Table 1.
Group 4 consists of 26 follow-up women with recurrent
ovarian cancer (median age 56 years, range 40–65).
Group 5 consists of 32 follow-up women with stable
ovarian cancer (median age 59 years, range 35–68).
All patients signed written informed consent to participate
in the study. At enrolment, medical history was collected and
peripheral blood samples were drawn and immediately sent to
the laboratory for analysis of 25-OH vitamin D.
Sample collection
Patient sera were acquired following a standard collection
protocol. Samples were collected in a Red Top Vacutainer,
clotted 60–90 min and centrifuged for 10 min at 1300×g.
The serum fractions were aliquoted and stored at −80 °C until
analysis.
Evaluation of EOC relapse
Recurrent EOC, unlike other solid tumors, tends to present
without accompanying symptoms and forms multiple small
implantations, particularly in the small intestine and mesen-
tery, which cannot be readily detected using conventional im-
aging techniques [16, 17]. Computed tomography (CT) has
low sensitivity for detecting disease recurrence, probably due
to its inability to detect small peritoneal implants and normal-
sized lymph node metastases [18, 19]. The following criteria
for recurrence of the disease (peritoneal carcinomatosis and
lymph node dissemination) were established in the follow-up
study
Table 1 Clinic pathological characteristics of the newly diagnosed
ovarian cancer patients (n=46)
Disease status Number Percent (%)
Histology Serous 24 52.17
Mucinous 6 13.0
Undifferentiated 13 28.26
Others 3 6.52
Grade 1 1 2.17
2 20 43.47
3 25 54.34
Stage I 6 13.0
II 5 10.86
III 6 13.00
IV 29 63.0
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(1) Peritoneal carcinomatosis. Single or multiple sites of
micro-nodular implants (<1 cm) above or below the
mesocolon; diffuse macro-nodular implants (>1.5 cm)
on the bowel surface or mesenterial implants; and omen-
tal involvement with marked thickening (omental cake).
(2) Lymph node dissemination. The onset of lymph node
>1 cm and/or the 20 % size increase of pre-existing
lymph nodes. Stable ovarian cancer was diagnosed when
the disease did not follow any of the parameters de-
scribed above.
Measurement of 25-OH vitamin D
25-OH vitamin D levels were measured with the
LUMIPULSE® G 1200 (Fujirebio, Japan), an assay system
that allows quantitative measurements and is based on chemi-
luminescent enzyme immunoassay (CLEIA) technology. The
LUMIPULSE® G 25-OH vitamin D uses a novel two-step
sandwich method [20] for detecting 25-OH vitamin D. The
assay uses a solid-phase and alkaline phosphatase (ALP)-la-
beled monoclonal antibodies that specifically bind to the ana-
lyte forming antigen–antibody immunocomplexes. ALP-
labeled monoclonal antibody binds to the antigen of the
immunocomplexes, and adamantyl-1,2-dioxetane phosphate
(AMPPD) contained in the substrate solution is dephosphor-
ylated by the catalysis of ALP indirectly conjugated to the
particles. A luminescent signal is generated by the cleavage
reaction of dephosphorylatedAMPPD and reflects the amount
of antigen in the sample.
Statistical analysis
The statistical significance of difference between the number
of patients affected by ovarian cancer and that of patients
affected by other benign pathologies showing values of the
25-OH deficiency was assessed using a chi-square test for
categorical variables. In terms of the diagnostic accuracy of
the assays, the performance was assessed by estimation of
receiver operating characteristic (ROC) curve for ovarian can-
cer cases versus benign gynecologic diseases. The area under
the ROC curve (AUC) was calculated by MedCalc V 4.30
Software.
Results
25-OH vitamin D normal levels in our healthy population
Sixty blood donors were included in this study. These samples
were obtained through a collaboration with the Blood Bank of
the Policlinico Umberto I. As a threshold value, identified by
ROC curve analysis, 20.2 ng/mL (sensitivity 73.3 %,
specificity 84%)was found to correspond to the limit between
sufficient and insufficient 25-OH vitamin D according to the
WHO (Fig. 1).
25-OH vitamin D levels in ovarian cancer
We evaluated 25-OH vitamin D values in 61 blood donors
(group 1), 45 patients with benign ovarian diseases (group
2), and 46 patients with recent diagnosis of ovarian cancer
(group 3). The patients were divided according to their 25-
OH vitamin D status into a deficient (<20 ng/mL) and a non-
deficient (>20 mg/mL) group. Insufficient levels of 25-OH
vitamin D were observed in 16/61 (26 %) group 1 women,
in 11/45 (24 %) Group 2 patients, and 34/46 (80 %) group 3
patients. We observed a statistical difference (p value <0.001)
between the values observed in ovarian cancer patients (group
3) versus benign gynecology diseases (group 2) patients and
healthy donors (group 1) (Fig. 2).
We also investigated the correlation of 25-OH vitamin D
concentrations with disease recurrence. We evaluated 25-OH
vitamin D levels in 58 patients divided in two groups of wom-
en affected by recurrent disease (group 4, n=26) and women
with stable disease (group 5, n=32). The follow-up study
showed an insufficient level of 25-OH vitamin D in 19/26
(73 %) women with recurrent ovarian cancer (group 4) and
in 16/32 (47 %) women with stable ovarian cancer (group 5)
(p<0.0003) (Fig. 3).
Discussion
Ovarian cancer, as a notorious Bsilent killer,^ is one of the
most lethal gynecological neoplasms in women living in
Fig. 1 ROC curve analysis for determining 25-OH Vitamin D
insufficiency. The threshold value was determined to be 20.2 ng/mL
(sensitivity 73.3 %, specificity 84 %) with an area under the ROC curve
0.811 (95 % CI 0.71–0.88)
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industrialized countries [21]. At present, the global annual
incidence is approximately 204,499 cases per year with a
mortality of 124,860 patients per year [22]. The expected
number of new ovarian cancer cases in Europe in 2012 was
65,538 with 42,704 deaths [1]. Due to the development of
surgery and chemotherapy with empirically optimized combi-
nations of conventional agents, survival rate of ovarian cancer
currently approximates 30 % [23]. If carcinoma is diagnosed
at an early stage, it has an excellent prognosis since it can be
treated before spreading to surrounding tissue [24].
Currently, as many as 70 % of patients are diagnosed at
International Federation of Gynecology and Obstetrics
(FIGO) stages III and IV. This late diagnosis is generally re-
lated to the asymptomatic behavior of the disease in the early
stages. Although certain EOC screening tests have been
shown to decrease mortality rates, the possibility of efficient
screening that may be used in normal practice remains elusive
[25, 26].
Recently, vitamin D has been found to be less expressed in
some cancers (breast, lung) [10]. Moreover, this decrease in
cancer could help discriminate between benign and malignant
diseases [27]. The present study confirmed the findings from
other cancers and demonstrated that 25-OH vitamin D is de-
creased at time of diagnosis in nearly all patients affected by
ovarian cancer and that only a small percentage of patients
affected by gynecological benign diseases had levels below
the cutoff for 25-OH vitamin D [10, 28]. These results could
be interpreted according to the 25-OH vitamin D antiprolifer-
ative effects and its ability to block cell mitosis in the G1 phase
[29].
In addition to the search of specific markers for the deter-
mination of the early stages of any cancer form, it is just as
important to find markers capable of following the remission
from disease as response to therapy and in the event of the
unfortunate recurrence of the disease.
At present, a multimodal approach including the utilization
of tumor biomarkers associated with ovarian cancer, besides
imaging techniques, seems to be the best strategy in the as-
sessment of tumor spread, recurrence, and/or the response to
treatment. CT and PET-CT play an important role in early
detection of recurrence ovarian cancer, even if there is no
agreement on which type of follow-up examination should
be used or when it should be employed. However, the value
of PET-CT is limited in areas of physiologic radiotracer accu-
mulation and in small implants size. Diffusion-weighted MRI
imaging may be advantages for overcoming dissemination.
The combined interpretation of diffusion-weighted images
with conventional MRI has been shown to increase accuracy
in the staging of ovarian cancer and in the follow-up [30].
Our study shows a higher percentage of vitamin D defi-
ciency in patients affected by disease recurrence in respect to
the group with stable disease, suggesting that vitamin D defi-
ciency could be a risk factor for disease recurrence. To this
aim, the synergy of vitamin D with other vitamins should be
studied to determine its relevance in the natural immunity and
blocking of angiogenesis. Recent studies with animal models
suggested potent anti-metastatic activities of 25-OH vitaminD
[31].
A broad scientific bibliography has established, enhanced,
and confirmed the preventive and therapeutic activity of 25-
OH vitamin D in neoplastic diseases. Recently, cellular recep-
tors (VDR) of 25-OH vitamin D have been identified and
proven to have anti-neoplastic effects [12]. A lot of studies
on synthetic, new-generation vitamin D are ongoing. They are
focused on reducing the calcemic activity that can produce, if
in excess, serious and irreversible damages and, meanwhile,
increase the anti-neoplastic rule in synergy with retinoid for
cellular differentiation activities. In addition to the in vitro and
animal model studies, clinical and epidemiologic studies also
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Fig. 2 Percentage of individuals affected by 25-OH vitamin D
insufficiency in healthy women (group 1), patients with benign
gynecology diseases (group 2), and patients affected by ovarian cancer
(group 3; * p<0.001)
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Fig. 3 Percentages of individuals with 25-OH vitamin D insufficiency at
follow-up in the group of patients with recurrence (group 4) and stable
disease (group 5; *p<0.0003)
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confirmed the anti-carcinogenic properties of 25-OH vitamin
D and its derivatives in tumoral prevention and therapy.
In conclusion, this study has shown that vitamin D may be
able to provide a valuable contribution both to the diagnosis of
ovarian cancer and to controlling its recurrence. Thus, the
search for biomarkers which (1) can predict as early as possi-
ble the occurrence of ovarian or other gynecological cancers
and (2) can foresee, in spite of treatment, the recurrence of
these diseases, can help in taking the fundamental steps need-
ed to control and, ultimately, find a definitive cure for these
diseases.
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